Semax: Cognitive Research and Limitations

What Is Semax?

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, a portion of adrenocorticotropic hormone associated with cognitive function rather than adrenal stimulation. It was developed in Russia and approved there for clinical use, though it remains unapproved in Western markets.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s. It is a modified analog of the naturally occurring ACTH(4-10) sequence, with an added Pro-Gly-Pro C-terminal tripeptide that extends its metabolic stability from minutes to hours.

The original ACTH(4-10) fragment was identified decades ago as the portion of ACTH responsible for cognitive and neurotrophic effects. It is distinct from the adrenal-stimulating properties of the full ACTH molecule. Semax was designed to retain and enhance these cognitive properties while eliminating hormonal effects on the adrenal axis.

In Russia, Semax has been approved since the late 1990s and is used clinically for cognitive impairment, stroke recovery, and optic nerve disease. It is available as a nasal spray in concentrations ranging from 0.1% to 1%.

Who this page is for, and who it isn’t for

This page is for researchers, clinicians, and individuals seeking a balanced review of the Semax evidence base. Most published clinical data originates from Russian research groups, and transparency about this limitation is maintained throughout. This page is not a treatment guide and does not constitute medical advice.

How Semax Is Thought to Work

Semax acts through multiple neurological pathways, with its primary effects attributed to neurotrophic factor modulation, monoaminergic system influence, and neuroprotective mechanisms.

BDNF and NGF Modulation

The most consistently reported mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).

BDNF is one of the most important molecules for neuroplasticity, the brain’s ability to form new connections, strengthen existing ones, and adapt to new information. It plays critical roles in learning, memory formation, and neuronal survival. NGF serves similar functions, particularly for cholinergic neurons involved in attention and memory.

Semax has been shown to increase BDNF expression in the hippocampus and basal forebrain of rats (Dolotov et al., 2006). The magnitude and time course of this effect appear dose-dependent, with effects persisting after cessation of administration, suggesting lasting neuroplastic changes rather than acute pharmacological effects. Researchers believe this persistence reflects changes in gene expression rather than ongoing receptor activation. The precise signaling cascade from Semax administration to sustained BDNF upregulation has not been fully mapped.

This neurotrophic mechanism distinguishes Semax from stimulant-type nootropics (caffeine, amphetamines) that enhance performance transiently without affecting underlying brain structure or connectivity.

Dopaminergic and Serotonergic Effects

Semax influences monoamine neurotransmitter systems, particularly dopamine and serotonin, though the exact mechanisms are not fully characterized.

Dopamine. Semax has been reported to increase dopamine levels and dopamine turnover in the striatum and nucleus accumbens in rodent studies. This effect is thought to contribute to its pro-cognitive and mood-enhancing properties. Unlike direct dopaminergic drugs (amphetamines, methylphenidate), Semax appears to modulate dopamine indirectly, potentially through effects on enkephalinase inhibition or through neurotrophic factor-mediated changes in dopaminergic neuron function (Eremin et al., 2005). How a short peptide fragment produces these monoaminergic effects is not fully understood. The proposed pathways are consistent with observed data but remain partly hypothetical.

Serotonin. Semax has been shown to influence serotonin metabolism in the brain, with reported increases in serotonin turnover in certain brain regions. The clinical relevance of this effect, and whether it contributes to reported mood effects, remains uncertain.

Neuroprotective Mechanisms

Semax has demonstrated neuroprotective effects in multiple experimental models:

• Anti-inflammatory. Semax reduces expression of pro-inflammatory cytokines (IL-1β, TNF-α) and increases anti-inflammatory cytokines in brain tissue following ischemic injury (Medvedeva et al., 2014).
• Anti-oxidative. Semax reduces markers of oxidative stress in neural tissue in animal models.
• Anti-apoptotic. Semax appears to inhibit programmed cell death pathways in neurons exposed to ischemic or toxic insults.
• Gene expression. Transcriptomic studies in rats have identified over 100 genes whose expression is modulated by Semax, spanning inflammation, neurotransmission, synaptic plasticity, and cell survival pathways (Medvedeva et al., 2014). The breadth of gene expression changes is notable but complicates interpretation. When a compound affects hundreds of genes, distinguishing therapeutically relevant changes from incidental ones becomes difficult.

What Semax Does Not Do

Despite being derived from ACTH, Semax does not stimulate the adrenal glands or increase cortisol production at studied doses. The ACTH(4-10) fragment lacks the N-terminal sequence (ACTH 1-3) required for adrenal stimulation. This is by design. The developers specifically selected the cognitive fragment and discarded the hormonal fragment.

Semax also does not appear to produce the “jittery” stimulation associated with caffeine or amphetamines. Community reports and clinical descriptions consistently describe its cognitive effects as “clean,” with enhanced focus and clarity without physical agitation.

What the Research Shows

The clinical evidence for Semax comes predominantly from Russian research groups. This is an important context for evaluating the data.

Russian Clinical Applications (Approved Indications)

Semax is approved in Russia for several clinical indications:

Cognitive dysfunction. Semax is prescribed for cognitive impairment associated with various conditions, including cerebrovascular disease, traumatic brain injury, and age-related cognitive decline. Clinical studies in Russian medical literature report improvements in attention, memory, and information processing (Kaplan et al., 1996).

Ischemic stroke. Semax (at higher concentrations, 1% nasal spray) has been studied as an adjunct treatment for acute ischemic stroke. Russian clinical data reports improved neurological outcomes and faster recovery when Semax is administered within the first hours to days following stroke onset (Gusev et al., 2005). The proposed mechanism involves neuroprotection of penumbral tissue — brain tissue at risk but not yet dead — through BDNF-mediated survival signaling and anti-inflammatory effects.

Optic nerve disease. Semax has been used clinically in Russia for optic nerve atrophy and other optic nerve disorders. The rationale involves neurotrophic support of retinal ganglion cells and optic nerve fibers. Clinical reports describe improved visual function in some patients, though the quality of this evidence by Western standards is limited.

The Evidence Quality Problem

It is necessary to address the quality of the clinical evidence directly.

Most Semax clinical studies were published in Russian-language journals, many of which are not indexed in major Western databases or are available only in translated abstracts. The full methodological details (randomization procedures, blinding, statistical analysis plans, intention-to-treat analysis) are often not accessible for independent evaluation.

This does not mean the research is fabricated or worthless. Russian pharmaceutical research has produced valid and important science. But the standards for clinical trial conduct, reporting, and peer review differ between regulatory environments, and independent replication by Western research groups is largely absent.

Where Evidence Is Limited or Conflicting

Even within the available literature, certain findings remain uncertain. Reported cognitive improvements in human studies are based on small sample sizes, often without placebo controls that meet current Western standards. Some animal studies report robust BDNF upregulation, while others find more modest or region-specific changes. The effect may be less uniform than initial reports indicated.

Additionally, no published pharmacokinetic studies have rigorously quantified whether intranasal delivery achieves consistent central nervous system concentrations in humans.

These are not reasons to dismiss the research. They do mean the confidence level for specific claims about Semax should remain moderate rather than high.

The situation is similar to that of Selank, Semax’s “sister peptide” developed by the same research institute. Both have interesting clinical data from Russia with limited independent verification. For a broader discussion of why this pattern exists, see why most peptide evidence is preclinical.

Preclinical Evidence (Animal Studies)

The animal data for Semax is more extensive and, because preclinical methodology is more standardized internationally, somewhat easier to evaluate.

Learning and memory. Semax improved performance in multiple rodent learning paradigms (passive avoidance tests, Morris water maze, novel object recognition) at doses ranging from 50 to 600 mcg/kg. Effects were observed both acutely and after repeated administration (Levitskaya et al., 2004).

Stroke models. In experimental middle cerebral artery occlusion (the standard rodent stroke model), Semax reduced infarct volume, improved neurological deficit scores, and attenuated inflammatory gene expression. The effect was dose-dependent and time-dependent, with earlier administration producing better outcomes.

BDNF and NGF upregulation. Multiple studies confirm that Semax increases BDNF and NGF expression in the hippocampus and cerebral cortex, consistent with its proposed neurotrophic mechanism.

Stress resilience. Semax improved behavioral outcomes in chronically stressed rodents, normalizing exploratory behavior, reducing anxiety-like behavior, and preserving cognitive performance under stress conditions.

Attention and impulsivity. In rat models of attention deficit, Semax improved sustained attention and reduced impulsive responding. This finding has generated interest in Semax for attention-related cognitive concerns, though human data for this indication is minimal.

Methodological Limitations

Several structural limitations affect the Semax evidence base as a whole.

Most human studies involved small cohorts, typically fewer than 100 participants, conducted at a small number of Russian institutions. Many used open-label designs or lacked the double-blinding and placebo controls expected in modern clinical research. Study durations were generally short, matching the standard 10-14 day Russian clinical protocol. This limits what can be concluded about sustained use.

Animal studies are more methodologically standardized but face the usual translational challenges. Effective doses in rodents do not reliably predict effective doses in humans. Behavioral models of cognition in rats capture only narrow aspects of human cognitive function.

These limitations do not invalidate the findings. They do constrain the certainty with which conclusions can be drawn.

What Has Not Been Studied Adequately

Despite the breadth of research, significant gaps remain:

• No Western clinical trials. No randomized controlled trials conducted under FDA or EMA oversight have been published.
• No long-term safety studies. Safety data beyond Russian clinical experience (typically courses of 10–14 days) is limited.
• No dose-response studies in humans meeting Western standards.
• No direct comparison trials with established cognitive enhancers (donepezil, memantine, or even caffeine).
• No pharmacokinetic studies in humans published in Western literature.
• Limited data on drug interactions.

Semax Variants

Several modified versions of Semax have been developed, primarily within the nootropic community.

N-Acetyl Semax (NASA)

N-Acetyl Semax adds an acetyl group to the N-terminus of the Semax molecule. Community reports suggest this modification increases potency and duration of action. However, the acetylated form has essentially no published research. The clinical and preclinical data that exists is for unmodified Semax. Any claims about N-Acetyl Semax are extrapolations from unmodified Semax data combined with community anecdotes.

N-Acetyl Semax Amidate (NASA Amidate)

This version adds both N-terminal acetylation and C-terminal amidation. It is described in community discussions as the most potent form. Again, published research supporting this claim is absent. The modifications are theorized to increase bioavailability and receptor binding, but these are theoretical arguments, not demonstrated effects.

Important caveat: Using a modified version of a molecule and assuming the same safety and efficacy profile applies is a pharmacological assumption, not a fact. Structural modifications can alter receptor selectivity, metabolic pathways, and side effect profiles in unpredictable ways. The evidence base applies to the studied molecule, unmodified Semax, not to its derivatives.

How Semax Compares to Related Compounds

Semax is often discussed alongside other nootropic and neuroprotective peptides.

Semax vs. Selank

Selank is Semax’s “sister peptide,” developed at the same institute. Both are Russian-developed, intranasally administered, and studied for cognitive effects. However, their pharmacological profiles differ:

• Semax is generally described as more activating: pro-dopaminergic, enhancing focus and attention, potentially stimulating.
• Selank is more calming: GABAergic, anxiolytic, with anti-anxiety effects as its primary clinical indication.
• Semax may increase anxiety in sensitive individuals (anecdotal reports). Selank specifically reduces anxiety.
• Both upregulate BDNF, but through different upstream mechanisms.

In community discussions, they are sometimes combined (Semax for cognitive drive, Selank for anxiety mitigation), though there is no clinical data on the combination.

Semax vs. DSIP

DSIP (Delta Sleep-Inducing Peptide) occupies a different niche, primarily studied for sleep architecture and stress modulation rather than cognitive enhancement. DSIP and Semax target different aspects of brain function and are not typically viewed as alternatives.

Semax vs. Epithalon

Epithalon is studied primarily for telomerase activation and pineal gland function, a fundamentally different mechanism from Semax’s neurotrophic approach. Both are sometimes discussed under the umbrella of “brain health” or “longevity,” but their mechanisms and evidence bases do not overlap significantly.

Semax vs. Conventional Nootropics

Compared to established cognitive enhancers:

• Caffeine has vastly more human data and a well-characterized mechanism (adenosine receptor antagonism). It enhances alertness but does not appear to promote neuroplasticity.
• Modafinil has strong clinical evidence for wakefulness and cognitive enhancement in sleep-deprived individuals. Its mechanism is partially understood and differs from Semax’s neurotrophic approach.
• Racetams (piracetam, aniracetam) have decades of research but mixed clinical results. Their mechanisms are not fully established.

Semax’s theoretical advantage is promoting lasting neuroplastic changes through BDNF rather than providing transient pharmacological enhancement. This is appealing but not confirmed in comparative human studies. Whether BDNF upregulation measured in rodent hippocampus translates to meaningful cognitive improvement in humans at achievable intranasal doses remains an open question.

Community-Reported Protocols

Community-reported protocols reflect the Russian clinical dosing literature and community experience. These should not be interpreted as recommendations.

Intranasal (Primary Route, Clinically Used in Russia)

• Formulation: 0.1% Semax nasal spray (standard); 1% (used in stroke research)
• Reported dose: 2–3 drops per nostril, 2–3 times daily
• Approximate dose per administration: 200–600 mcg (0.1% solution)
• Reported daily total: 600–1800 mcg (0.6–1.8 mg)
• Reported duration: 10–14 day courses (Russian clinical protocols); some community members report longer use
• Rationale for intranasal route: Direct access to the central nervous system via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier and first-pass metabolism

Subcutaneous Injection (Community Protocol)

• Reported dose: 200–1000 mcg per injection
• Reported frequency: 1–2 times daily
• Reported duration: 10–30 days
• Note: Subcutaneous injection is a community adaptation, not the clinically studied route. Intranasal delivery is the route used in Russian clinical practice and the majority of published research.

Cycling

Russian clinical protocols prescribe Semax in courses of 10–14 days, sometimes repeated after a break. Community protocols often follow similar cycling patterns — 2–4 weeks on, 1–2 weeks off. Whether cycling is necessary (i.e., whether tolerance develops with continuous use) is not clearly established. Some community members report sustained effects with continuous use; others report diminishing returns.

Side Effects and Safety Considerations

Semax has a mild reported side effect profile in clinical use, though comprehensive safety data is limited to Russian clinical experience.

Reported Side Effects

• Nasal irritation. The most commonly reported side effect with intranasal use; generally mild and transient.
• Headache. Occasionally reported, typically at higher doses.
• Anxiety/overstimulation. Some individuals report increased anxiety, particularly at higher doses or in combination with stimulants. This contrasts with Selank, which is specifically anxiolytic.
• Insomnia. Reported when Semax is taken later in the day, consistent with its activating properties.
• Fatigue upon discontinuation. Some community members report a period of reduced motivation or cognitive clarity when stopping after extended use. Whether this represents withdrawal, return to baseline, or simply contrast effect is unclear.

Notable Safety Observations

• No adrenal effects. Despite its ACTH derivation, Semax does not appear to affect cortisol levels or adrenal function at studied doses.
• No reported dependence. Physical dependence has not been documented in clinical use or community reports.
• Limited cardiovascular effects. Semax does not appear to increase heart rate or blood pressure significantly, distinguishing it from stimulant nootropics.
• No significant hormonal effects beyond the neurotrophic systems it targets.

Limitations

• Safety data is predominantly from Russian clinical experience of limited duration (10–14 day courses).
• Long-term safety with continuous use has not been systematically evaluated.
• Drug interaction data is sparse — caution is warranted when combining with psychiatric medications, particularly MAO inhibitors or dopaminergic drugs.
• Safety in pregnancy, lactation, and pediatric populations has not been established.

For broader context on peptide safety, see our peptide safety guide.

What’s Claimed vs. What’s Supported

The online nootropic community attributes a wide range of effects to Semax. Transparency about what is and isn’t supported matters.

Claim	Evidence Level
Improves focus and attention	Moderate (Russian clinical data + animal studies)
Enhances memory	Moderate (Russian clinical data + animal studies)
Increases BDNF	Strong (multiple preclinical studies)
Neuroprotective after stroke	Moderate (Russian clinical data + animal models)
Treats ADHD	Weak (some animal data; no human trials for this indication)
Cures depression	Not supported (may have mood effects, but no clinical depression trials)
Increases intelligence permanently	Not supported
No side effects	Incorrect (mild side effects are documented)
Works identically to modified variants (NASA, amidate)	Not supported (modifications are not studied)

The honest summary: Semax has interesting data supporting cognitive and neurotrophic effects, but the evidence quality is limited by its geographic concentration and lack of Western clinical validation. For guidance on evaluating such claims, see how to read peptide claims critically.

Regulatory and Legal Status

Russia

Approved as a nootropic and neuroprotective medication. Available as nasal spray by prescription.

United States

Not FDA-approved. Not a controlled substance. Available as a research chemical.

European Union

Not approved. Available as a research chemical in most EU countries.

WADA

Semax is not currently listed on the WADA Prohibited List, though ACTH itself is prohibited. The distinction is based on Semax’s lack of adrenal effects.

Frequently Asked Questions

Is Semax a stimulant?

Not in the traditional sense. Semax does not work through the mechanisms that define stimulants (dopamine/norepinephrine reuptake inhibition, adenosine antagonism). However, its dopaminergic effects and activating properties mean some users experience increased alertness and focus that feels stimulant-like. It does not produce the cardiovascular stimulation, appetite suppression, or crash associated with stimulant drugs.

How quickly does Semax work?

Intranasal Semax is reported to produce noticeable cognitive effects within 15–30 minutes for acute effects. Neurotrophic benefits (BDNF upregulation, lasting cognitive improvement) are expected to develop over days to weeks of consistent use, as they depend on gene expression changes and neuroplastic remodeling.

Can Semax be used with Selank?

This combination is commonly discussed in nootropic communities — Semax for cognitive enhancement, Selank for anxiety modulation. No clinical data exists on the combination. The theoretical rationale is that Selank’s GABAergic, anxiolytic effects would counterbalance any Semax-induced overstimulation. This is plausible mechanistically but unverified clinically.

Is N-Acetyl Semax better than regular Semax?

There is no published research on N-Acetyl Semax (NASA) or N-Acetyl Semax Amidate (NASA Amidate). These variants are popular in nootropic communities based on theoretical arguments about improved bioavailability and community experience reports. All published clinical and preclinical data pertains to unmodified Semax. Whether the modifications improve, maintain, or alter the efficacy and safety profile is unknown.

Does Semax affect cortisol?

At studied doses, no. Despite being derived from ACTH, Semax specifically retains the cognitive fragment (positions 4-10) while lacking the adrenal-stimulating fragment (positions 1-3). Multiple studies confirm no significant effect on cortisol or adrenal function. This was a deliberate design choice by its developers.

Why isn’t Semax approved outside Russia?

The same reasons most non-Western peptides lack approval globally: the clinical trial data required for FDA or EMA approval (large-scale, multi-center, Phase III trials) has not been conducted, likely due to the cost (hundreds of millions of dollars), patent challenges, and the fact that the existing Russian approval process does not satisfy Western regulatory requirements. For a broader discussion, see why most peptide evidence is preclinical.

References

1. Dolotov OV, et al. “Semax, an analogue of ACTH(4-10) with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus.” Int J Dev Neurosci. 2006;24(4-5):283-289. PubMed
2. Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500. PubMed
3. Medvedeva EV, et al. “The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228. PubMed
4. Kaplan AY, et al. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neurosci Res Commun. 1996;19(2):115-123. PubMed [research needed — exact PMID to verify]
5. Gusev EI, et al. “Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency.” Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. PubMed [research needed — exact PMID to verify]
6. Levitskaya NG, et al. “Investigation of the spectrum of physiological activities of the peptide Semax.” Neurosci Behav Physiol. 2004;34(8):795-800. PubMed [research needed — exact PMID to verify]
7. Ashmarin IP, et al. “Glyprolines and their analogues.” Biochemistry (Mosc). 2002;67(2):184-194.
8. Agapova TY, et al. “The neuroprotective effect of Semax in conditions of global cerebral ischemia.” Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(4):52-55. [research needed]

Related Articles

Peptide

Epithalon (Epitalon): Research, Mechanism, and a Careful Look at the Anti-Aging Evidence

An evidence-based review of Epithalon — the tetrapeptide studied for telomerase activation, melatonin restoration, and lifespan extension. What the data supports and where it falls short.

Peptide

DSIP (Delta Sleep-Inducing Peptide): Research, Mechanism, and Evidence for Sleep Modulation

An evidence-based review of DSIP — the nonapeptide studied for delta wave sleep enhancement, stress hormone regulation, and neuroendocrine modulation. What the data shows and what remains unknown.

Peptide

Selank: Research, Mechanism, and Clinical Evidence for Anxiety and Cognition

An evidence-based review of Selank — the tuftsin-derived heptapeptide studied for anxiolytic and nootropic effects. Russian clinical data, mechanism of action, and what is known.